Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2021-12-31 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
CHANGE OF COMPANY NAME OF NON-HONG KONG COMPANY AND CHANGE OF STOCK SHORT NAME
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's name and stock short name. It includes details about the registration of the new company name with the Market Supervision Administration and the Registrar of Companies in Hong Kong, as well as the effective date of the stock short name change. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management discussion. The document is a regulatory announcement about corporate identity changes, not a financial report or meeting material. Given the short length (3428 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-31 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-12-31 English
ANNOUNCEMENTS IN RELATION TO AMENDMENT TO THE RESTRICTED A SHARE INCENTIVE SCHEME FOR 2021 (DRAFT) AND ITS SUMMARY
Capital/Financing Update Classification · 95% confidence The document is an announcement from Yankuang Energy Group Company Limited regarding amendments to the Restricted A Share Incentive Scheme for 2021. It details changes to performance appraisal targets and references prior announcements and resolutions by the Board and Supervisory Committee. The document is not a full financial report, earnings release, or management discussion, but rather a corporate announcement about changes to an incentive scheme. It does not contain financial statements or detailed financial analysis. It is also not a proxy solicitation or voting result announcement. Given the nature of the content—amendments to a share incentive scheme and related administrative measures—this fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including share incentive schemes.
2021-12-31 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-12-31 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-12-31 English
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals regarding unusual price and trading volume movements of its shares. It explicitly states it is an announcement and does not contain any financial statements, detailed financial data, or report content. The document is relatively short (4209 characters) and serves to inform shareholders and investors about the situation and the company's current status. It does not present an annual report, earnings release, or any detailed financial or management report. It is a regulatory announcement related to market activity and company status without substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-28 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.